Orbit Discovery and Evergreen Theragnostics expand research collaboration

Partnership aims to develop new radiopharmaceuticals for cancer treatment

Orbit Discovery, based in Oxford, UK, and Evergreen Theragnostics, headquartered in Springfield, NJ, USA, have announced the expansion of their collaborative research agreement. This partnership seeks to discover new targeting peptides for radiopharmaceutical delivery, building on their initial agreement from April 2023.

Through this extended collaboration, Orbit Discovery will utilise its proprietary screening platform to identify and optimise peptide candidates. Evergreen Theragnostics will contribute its expertise in radiopharmaceutical development and clinical translation.

The combined efforts of both companies aim to advance next-generation targeted therapies with a focus on speed, precision, and efficacy.

Dr Neil Butt, CEO of Orbit Discovery, highlighted the success of the partnership, stating, “Our collaboration with Evergreen Theragnostics has proven to be a powerful example of how complementary expertise can drive ground-breaking innovation. We are excited to continue building on our achievements and leveraging our proprietary platform to discover peptides with therapeutic potential.”

Dr Butt added that Evergreen Theragnostics’ radiopharmaceutical expertise provides a strong foundation for transforming these peptides into advanced therapies, particularly in oncology. “The partnership exemplifies the commitment of both companies to delivering patient-centric solutions in the rapidly expanding radiopharmaceutical market,” he said.

Dr Thomas Reiner, CSO of Evergreen Theragnostics, expressed enthusiasm for the ongoing partnership, saying, “We are thrilled to extend our collaboration with Orbit Discovery. The company’s peptide discovery platform has proven invaluable in our mission to develop precision-targeted radiopharmaceuticals. Together, we aim to expedite the journey from discovery to clinical application, creating novel therapies with the potential to improve outcomes for cancer patients.”

The expanded collaboration underscores a shared vision to advance targeted therapeutic development, with the potential to significantly impact the field of precision medicine.